Conference Presentations
PLENARY SESSIONS
-
THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
-
THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
-
THIRD PLENARY SESSION: EVOLUTION OF VALUE: PERSPECTIVES FROM BOTH SIDES OF THE ATLANTIC
Presentation
Mandy Ryan
PhD, MSc, Director of the Health Economics Research Unit, Institute of Applied Health Sciences, College of Life Sciences and Medicine, University of Aberdeen, Aberdeen, UK
-
SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?
Presentation
Zoe Garrett
MRes, MPhil, Technical Adviser, National Institute for Health and Care Excellence (NICE), Centre for Health Technology Evaluation, London, UK
-
SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?
Presentation
Nicola Allen
PhD, Senior Consultant, Global Pricing and Product Strategy, Precision Xtract, London, UK
-
SECOND PLENARY SESSION: APPRAISING THE APPRAISERS: WHAT IS THE FUTURE OF HEALTH TECHNOLOGY ASSESSMENT IN EUROPE?
-
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
Presentation
Luke Slawomirski
Health Economist & Policy Analyst, Directorate for Employment, Labour and Social Affairs, Organisation for Economic Co-operation and Development (OECD), Paris, France
-
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
-
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
Presentation
Bettina Ryll
MD, PhD, Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
-
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
Presentation
Peter Naredi
Professor of Surgery & Head, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg and President, European CanCer Organization (ECCO), Brussels, Belgium
-
FIRST PLENARY SESSION: WHERE IS THE VALUE IN VALUE-BASED HEALTH CARE?
Presentation
Maarten J. IJzerman
PhD, Professor & Chair, University of Twente and MIRA Institute for Biomedical Technology & Technical Medicine, Department of Health Technology & Services Research, Enschede, The Netherlands
ISSUE PANEL PRESENTATIONS
-
IP1 : PRAGMATIC CLINICAL TRIALS TO ESTIMATE TREATMENT EFFECTS: ARE THEY WORTH THE EFFORT?
Presentation
Rita M. Kristy
MS, Director - Statistics, Clinical and Outcomes Sciences, Astellas Pharma Global Development, Northbrook, USA
Keith R. Abrams
PhD, CStat, Professor of Medical Statistics, NIHR Senior Investigator Emeritus & Head, Biostatistics Research Group, University of Leicester, Department of Health Sciences, Leicester, UK
Christoph Gerlinger
PD, Senior Director, Bayer AG, Development, Pharmaceuticals, Berlin, Germany
-
IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?
Presentation
Jens Grueger
PhD, Vice President, Head of Global Health Economics & Pricing, F. Hoffmann-La Roche, Global Health Economics & Pricing, Basel, Switzerland
-
IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?
Presentation
Karl Claxton
PhD, Professor of Economics, University of York, Centre for Health Economics and Department of Economics, Heslington, York, UK
-
IP10 : DOES VALUATION OF INNOVATION IN APPRAISAL OF NEW TECHNOLOGIES PROVIDE APPROPRIATE INCENTIVES FOR MANUFACTURERS AND ACCESS FOR PATIENTS?
-
IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?
Presentation
Michael Schlander
MD, PhD, MBA, Chairman & Scientific Director, University of Heidelberg, Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany
-
IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?
Presentation
Alistair Mcguire
PhD, Professor of Health Economics, London School of Economics, London, UK
-
IP11 : DETERMINING VALUE IN HEALTH TECHNOLOGY ASSESSMENT CONSISTENT WITH SOCIETAL AIMS: PURSUE NEW OPTIONS?
Presentation
John Brazier
PhD, MSc, Professor of Health Economics and Dean, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK
-
IP12 : WHAT SHOULD PATIENT-CENTERED CARE MEAN IN THE WELFARE STATES OF EUROPE? THE UNITED KINGDOM AND GERMANY CANNOT BOTH BE RIGHT
Presentation
F. Reed Johnson
PhD, Senior Research Scholar, Duke University, Duke Clinical Research Institute, Durham, USA
Axel C. Mühlbacher
PhD, MBA, Professor of Health Economics and Health Care Management, Hochschule Neubrandenburg, Institute Health Economics and Health Care Management, IGM, Neubrandenburg, Germany
-
IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?
Presentation
Katharine Barnard
PhD CPsychol AFBPsS, Visiting Professor, Bournemouth University, Poole, UK
Francois Meyer
PhD, Advisor to the President, Haute Autorité de Santé (HAS), International Affairs, Saint-Denis, France
Simon O'Neill
REG.N., Director of Health Intelligence and Professional Liaison, Diabetes UK, London, UK
-
IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?
Presentation
Katharine Barnard
PhD CPsychol AFBPsS, Visiting Professor, Bournemouth University, Poole, UK
-
IP14 : PATIENT-CENTERED DECISION MAKING: HOW DO YOU GENERATE RELEVANT PATIENT-REPORTED OUTCOMES EVIDENCE FOR CHRONIC DISEASE MANAGEMENT AND MARKET-ACCESS DECISION MAKING?
Presentation
Finn Børlum Kristensen
MD, PhD, Professor, Health Services Research & Health Technology Assessment, Danish Health and Medicines Authority, University of Southern Denmark and Director, EUnetHTA Secretariat, Copenhagen, Denmark
-
IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?
Presentation
Charles D. Petrie
PhD, Vice President, Outcomes and Evidence, Pfizer, Inc., Global Health & Value, Groton, USA
-
IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?
Presentation
Roman Casciano
MS, Executive Vice President and Head, Value and Access, LASER Analytica, New York, USA
-
IP15 : A MODEST PROPOSAL: CAN WE EASE THE BURDEN OF MYRIAD MEASURES WITH A MINIMUM DATA SET THAT ACTUALLY MATTERS TO PATIENTS?
-
IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?
Presentation
Richard Charter
MSc, Head of Market Access & Pricing Diabetes Care Europe, Becton Dickinson AG, Allschwil, Switzerland
-
IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?
-
IP16 : MANAGED ENTRY SCHEMES FOR MEDICAL DEVICES: GREAT OPPORTUNITY OR MAJOR CHALLENGE?
Presentation
Michael Drummond
MCom, DPhil, Professor of Health Economics, University of York, Centre for Health Economics, Heslington, York, UK
-
IP18 : HOW WILL HEALTH CARE SYSTEMS HANDLE FUTURE ONCOLOGY COMBINATION PRODUCT LAUNCHES?
Presentation
Bettina Ryll
MD, PhD, Founder, Melanoma Patient Network Europe and Chair, Patient Advocates Working Group, European Society for Medical Oncology (ESMO), Uppsala, Sweden
-
IP19 : CAN THE PATIENT VOICE BE BETTER INCORPORATED INTO THE NICE PROCESS?
Presentation
Jennifer Lee
MBA, HEMAR & Advocacy Director, Janssen UK, Health Economics, Market Access, Reimbursement, & Advocacy, High Wycombe, UK
Eric Low
NA, Former CEO of Myeloma UK, N/A, East Lothian, UK
Heidi Livingstone
BA, Project Manager, Patient and Public Involvement Manager, NICE, London, UK
Richard Jackson
PGCE, NPQH, Patient Expert (Currently a Primary School Headteacher), NA (Hillview Primary School), NA, UK
-
IP9 : SHOULD RARE ONCOLOGY TREATMENTS BE CONSIDERED TRUE ORPHANS?
Presentation
Elangovan Gajraj
MSc, Senior Technical Adviser, National Institute for Health and Care Excellence, Scientific Advice, London, UK
Annabel Griffiths
PhD, Consultant, Costello Medical Consulting Ltd, Cambridge, UK
Ivana Cattaneo
MBA, Public Affairs Director, Novartis Farma S.p.A, Novartis Oncology Europe, Origgio (VA), Italy
Pan Pantziarka
PhD, Project Co-ordinator, Anti-Cancer Fund, Strombeek-Bever, Belgium
WORKSHOP PRESENTATIONS
-
W1 : WHERE DO WE NEED GOOD RESEARCH PRACTICE GUIDANCE IN HEALTH TECHNOLOGY ASSESSMENT?
Presentation
Mirjana Huić
MD, PhD, Assistant Director, Agency for Quality and Accreditation in Health Care and Social Welfare, Department for Development, Research and Health Technology Assessment, Zagreb, Croatia
Sophie Werkö
PhD, MSc, Project Director, Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU), Stockholm, Sweden
-
W10 : EQ-5D: IS NICE READY FOR THE NEXT LEVEL?
Presentation
Rosemary Lovett
PhD, Senior Scientific Adviser, National Institute for Health and Care Excellence (NICE), Science Policy and Research Programme, London, UK
-
W10 : EQ-5D: IS NICE READY FOR THE NEXT LEVEL?
Presentation
Allan Wailoo
MA, MSc, PhD, Professor of Health Economics, University of Sheffield, School of Health and Related Research, Sheffield, UK
-
W17 : COMPARING, CONTRASTING, AND VALIDATING HEALTH ECONOMIC DECISION MODELS: EXPERIENCES FROM THE LATEST MT. HOOD CHALLENGE IN DIABETES AND LESSONS FOR OTHER DISEASE AREAS
Presentation
Mark Lamotte
MD, Cardiologist, Senior principal, QuintilesIMS, RWES, Zaventem, Belgium
Michael Willis
PhD, Research Director, The Swedish Institute for Health Economics, Lund, Sweden
Talitha Feenstra
PhD, Senior Researcher / Assistant Professor, RIVM /UMCG, Bilthoven, The Netherlands
-
W18 : FROM ONE TO MANY: WHEN GROUPS – NOT CZARS – MAKE DECISIONS
Presentation
Guruprasad Madhavan
PhD, Senior Program Officer, National Academies of Science, Engineering, and Medicine, Health and Medicine, Washington, USA
-
W2 : PATIENT POWERED REGISTRIES: USEFUL FOR HEALTH TECHNOLOGY ASSESSMENT OR NOT?
Presentation
Elisabeth M. Oehrlein
BA, PhD Candidate, University of Maryland, School of Pharmacy, Pharmaceutical Health Services Research, Baltimore, USA
Robert N. McBurney
PhD, Chief Executive Officer, Accelerated Cure Project for Multiple Sclerosis, Waltham, USA
Gurmit Sandhu
B Pharm (Hons), MBA, MPH, Patient Engagement Specialist, Gurmit Sandhu Consulting GmbH, Basel, Switzerland
Chantal Guilhaume
PharmD, Scientific Project Manager, EUnetHTA JA3; Direction de l'Evaluation Médicale, Economique et de Santé Publique (DEMESP), Haute Autorité de Santé, Saint-Denis La Plaine, France
-
W21 : COMPARING TREATMENTS BY COMBINING DATA FROM VARIOUS RANDOMIZED AND OBSERVATIONAL STUDIES: INTRODUCTION TO CONCEPT, METHODS, AND APPLICATION
Presentation
Farhan Mughal
MRPharmS, MSc, Associate Director, Celgene Ltd, Health Economics and Outcomes Research, Uxbridge, UK
Susanne Schmitz
PhD, Postdoctoral Fellow, Luxembourg Institute of Health, Department of Population Health / Health Economics and Evidence Synthesis Research Unit, Strassen, Luxembourg
Viktor Chirikov
PhD, Scientist, Pharmerit International, Bethesda, USA
-
W22 : NEGOTIATING PRICE AND DATA IN AN ERA OF CONDITIONAL APPROVAL: “STICK” OR “TWIST”?
Presentation
Daniel Gladwell
MSc, Principal Consultant, BresMed Health Solutions LTD, Sheffield, UK
Alan Brennan
PhD, Professor of Health Economics and Decision Modelling, University of Sheffield, School of Health and Related Research (ScHARR), Sheffield, UK
Warren Cowell
MSc, National Market Access Policy Lead, Janssen Inc., High Wycombe, UK
Ash Bullement
BSc, Health Economist, BresMed Health Solutions, Sheffield, UK
-
W23 : IMPROVING PERFORMANCE OF ALGORITHMS TO POWER UNMET NEED AND EFFECTIVENESS IN HEALTH ECONOMICS AND OUTCOMES RESEARCH USING ELECTRONIC HEALTH RECORDS AND HEALTH CARE CLAIMS DATA SOURCES
Presentation
Schiffon L Wong
MPH, Franchise Head Neurology, Global Evidence & Value Development, EMD Serono, Inc., Global Research & Development, Billerica, USA
Aaron WC Kamauu
MD, MS, MPH, CEO, Anolinx LLC, Salt Lake City, USA
Hoa Van Le
MD, PhD, Senior Consultant, PAREXEL INTERNATIONAL, DURHAM, USA
Monica Gaines Kobayashi
PhD, MBMA, Consultant, PAREXEL International, Real World Evidence & Data Analytics, Durham, USA
-
W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES
Presentation
David M. Phillippo
MSc, BSc, Research Associate in Evidence Synthesis, University of Bristol, School of Social and Community Medicine, Bristol, UK
-
W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES
-
W24 : POPULATION-ADJUSTED TREATMENT COMPARISONS IN HEALTH TECHNOLOGY ASSESSMENT: AN OVERVIEW OF APPROACHES AND PERSPECTIVES
Presentation
Nicky J. Welton
PhD, MSc, Reader in Evidence Synthesis, University of Bristol, School of Social and Community Medicine, Bristol, UK
-
W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
-
W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
-
W5 : SUSTAINABLE FUNDING AND FAIR PRICING FOR ORPHAN DRUGS: WHAT ARE THE SOLUTIONS?
-
W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
-
W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
-
W6 : GENERATING REAL-WORLD EVIDENCE FOR REAL-WORLD DECISIONS: APPLICATION OF ADVANCED METHODS
Presentation
Richard Grieve
PhD, Professor of Health Economics Methodology, London School of Hygiene and Tropical Medicine, London, UK
-
W7 : VALUE OF INFORMATION (VOI) ANALYSIS FOR RESEARCH DECISIONS: EMERGING GOOD PRACTICE RECOMMENDATIONS FROM THE ISPOR VOI TASK FORCE
Presentation
Claire Rothery
PhD, Senior Research Fellow in Health Economics, University of York, Centre for Health Economics, York, UK
Hendrik Koffijberg
PhD, Associate Professor Health Economics, University of Twente, Health Technology & Services Research, Enschede, The Netherlands
Saskia Knies
PhD, Policy Advisor Health Economics, National Health Care Institute (ZiN), Diemen, The Netherlands
Elisabeth Fenwick
PhD, Director, ICON Clinical Research, Health Economics, Oxford, UK
-
W8 : MODELING SEPARATE LINES OF TREATMENT VERSUS TREATMENT SEQUENCES IN CANCER
Presentation
Sonja Sorensen
MPH, Senior Director, Senior Research Leader, Evidera, Modeling & Simulation, Bethesda, USA
Matthew Stevenson
PhD, Professor of Health Technology Assessment, University of Sheffield, School of Health and Related Research, Sheffield, UK
ISPOR FORUMS
-
F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
-
F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
-
F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
Presentation
Maria Kamusheva
PhD, Assistant Professor, Medical University of Sofia, Faculty of Pharmacy, Sofia, Bulgaria
-
F10 : THE BURDEN OF COPD IN CENTRAL & EASTERN EUROPE
Presentation
Josip Culig
MD, PhD, President, ISPOR Croatia Chapter and Professor, Pharmacology & Clinical Pharmacology & Head, Public Health Institute Zagreb, Pharmacoepidemiology Department, Zagreb, Croatia
-
F2 : METHODS AND PRELIMINARY RESULTS OF THE ISPOR ONCOLOGY HEALTH ECONOMIC MODELING SPECIAL INTEREST GROUP
Presentation
Noemi Muszbek
MSc, Senior Research Scientist, Evidera, London, UK
Hena Qureshi
BSc BA, Student, University of Calgary, Community Health Sciences, Calgary, Canada
Agnes Benedict
MSc, Executive Director, Evidera, Budapest, Hungary
Nermeen Nabil Ashoush
PhD, Lecturer in Clinical Pharmacy and Pharmacy Practice Department, Faculty of Pharmacy, The British University in Egypt, Cairo, Egypt
-
F3 : RARE DISEASE RESEARCH, HTA AND EVIDENCE FOR REIMBURSEMENT
Presentation
Ken Redekop
PhD, Associate Professor, Erasmus University Rotterdam, Rotterdam, The Netherlands
Sheela Upadhyaha
BSc, Associate Director Highly Specialised Technologies, National Institute for Health and Care Excellence, Centre for Health Technology Evaluation, London, UK
Christopher M. Blanchette
PhD, MBA, Associate Dean, Research & Public Engagement, University of North Carolina at Charlotte, Charlotte, USA
Sandra Nestler-Parr
PhD, MSc, MBA, Head of Rare Diseases, Roboleo & Co, Leamington Spa, UK
Janis Clayton
BSc, VP and General Manager UK & Ireland, PTC Therapeutics Ltd., Dublin, Ireland
-
F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
-
F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
Presentation
Diego Rosselli
MD, MEd, MSc, Associate professor, Pontificia Universidad Javeriana, Clinical Epidemiology and Biostatistics Department, Bogota, Colombia
-
F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
Presentation
Diego F Guarin
MD, MPH, MA, Senior Director, HEOR & HTA Strategy, Merck-Serono, HEOR & HTA, Latin America, Billerica, USA
-
F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
Presentation
Federico Augustovski
MD, MSc, PhD, Director, Institute for Clinical Effectiveness and Health Policy (IECS), Health Techonology Assessment and Health Economic Department, Buenos Aires, Argentina
-
F4 : COULD MULTI-STAKEHOLDER PARTNERSHIP IMPROVE PATIENT ACCESS TO BETTER HEALTHCARE IN LATIN AMERICA?
-
F5 : RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Presentation
John Yfantopoulos
PhD, President, ISPOR Greece Chapter and Professor of Health Economics, University of Athens, School of Economics and Political Science, Athens, Greece
-
F5 : RARE DISEASES MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Presentation
Olha Zaliska
PhD, DSci (Pharm), President, ISPOR Ukraine Chapter and Professor, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine
-
F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
-
F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
Presentation
Dragana Atanasijevic
MD, MSc, President, ISPOR Serbia Chapter, and Consultant, HTA & Healthcare Quality Improvement, Belgrade, Serbia
-
F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
-
F6 : THE ESTABLISHMENT OF NEGOTIATION COMMITTEE, THERAPEUTIC GUIDELINES AND HEALTH TECHNOLOGY ASSESSMENT EFFORTS IN CEE COUNTRIES
-
F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Presentation
Bertalan Nemeth
MSc, Senior Health Economist, Syreon Research Institute, Budapest, Hungary
-
F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Presentation
Aleksandra Zawodnik
MSc Pharm, PhD Candidate, Medical University of Warsaw, Department of Experimental and Clinical Pharmacology, Warsaw, Poland
-
F9 : LATE STAGE ONCOLOGY MCDA CRITERIA IMPLEMENTATION RESULTS IN EUROPEAN COUNTRIES
Presentation
Oresta Piniazhko
MSPharm, PhD student, Danylo Halytsky Lviv National Medical University, Lviv, Ukraine